DUBLIN--(BUSINESS WIRE)--The "2018 Alcoholic Hepatitis Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Around 20 companies and universities are focusing on developing treatment options for Alcoholic Hepatitis.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Alcoholic Hepatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Alcoholic Hepatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- DS Biopharma
- DURECT Corporation
- Generon Corporation (Shanghai) Ltd.
- Gilead Sciences
- GRI Bio
- Hadasit Medical Research Services & Development Ltd
- Intercept Pharmaceuticals
- Promethera Biosciences
- Sumitomo Dainippon Pharma Co Ltd
- Vectus Biosystems Ltd
- Vital Therapies
Key Topics Covered
1 Table of Contents
2 Alcoholic Hepatitis Pipeline Analysis
3 Alcoholic Hepatitis - Company-wise Pipeline Analysis
4 Alcoholic Hepatitis R&D Pipeline Snapshots
5 Recent Developments in Alcoholic Hepatitis Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/zbl2lz/alcoholic?w=4